|
Affiliation |
Graduate School of Medicine Doctorial Course in Medicine Oncoregulatory Medicine Department of Clinical Oncology |
FUKUDA Koji
|
|
|
Graduating School 【 display / non-display 】
-
-2004.03
Sapporo Medical University Faculty of Medicine Graduated
Graduate School 【 display / non-display 】
-
-2017.03
Akita University Graduate School, Division of Medicine Doctor's Course Completed
Campus Career 【 display / non-display 】
-
2023.04-Now
Akita University Graduate School of Medicine Doctorial Course in Medicine Oncoregulatory Medicine Lecturer
-
2019.04-2023.03
Akita University Graduate School of Medicine Doctorial Course in Medicine Oncoregulatory Medicine Assistant Professor
-
2017.06-2019.03
Akita University School of Medicine Endowed Departments Assistant Professor appointed to endowed chairs
Thesis for a degree 【 display / non-display 】
-
A diarylpentanoid curcumin analog exhibits improved radioprotective potential in the intestinal mucosa
Koji Fukuda, Yoshihiko Uehara, Eiko Nakata
International Journal of Radiation Biology 92 ( 7 ) 388 - 394 2017.03
Domestic Co-author
Research Achievements 【 display / non-display 】
-
PD-L1 expression in keratinocyte and infiltration of CD4 + T lymphocyte can predict a severe type of erythema multiforme major induced by the anti-PD-1 antibody, pembrolizumab.
Ryohei Kadoi, Taichi Yoshida, Mai Noto, Aya Toyoshima, Sino Fujii, Koji Fukuda, Kazuhiro Shimazu, Daiki Taguchi, Hanae Shinozaki, Naoki Kodama, Michihiro Kono, Hiroshi Nanjyo, Hiroyuki Shibata
International cancer conference journal 13 ( 3 ) 268 - 274 2024.07
Research paper (journal)
UNLABELLED: Skin toxicity is the most common adverse event of treatment with immune check point inhibitors. Among them, erythema multiforme is a rare occurrence with a frequency of 4%, with most of the cases developing grade 1/2 disease. We experienced high grade erythema multiforme major developing with pembrolizumab treatment for anal canal cancer with extensive skin metastases. Steroid ointment was ineffective, and the skin lesions with blisters expanded to > 45% of the body surface area. The patient was at risk for symptom aggravation, and a pulse therapy with methylprednisolone and increasing the dose of oral prednisolone (1 mg/kg) were started. The skin lesions improved in 1.8 months. Unless urgent and appropriate treatments such as high dose steroid administration were conducted, the skin toxicities could not be controlled. The presence of CD4+ T cells and PD-L1+ keratinocytes in the skin biopsy might be a predictive marker of erythema multiforme major resistant to standard steroid treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13691-024-00676-4.
-
Recent trends in bone metastasis treatments: A historical comparison using the new Katagiri score system.
Kenji Matsuda, Kazuhiro Shimazu, Hanae Shinozaki, Koji Fukuda, Taichi Yoshida, Daiki Taguchi, Kyoko Nomura, Hiroyuki Shibata
World journal of clinical cases 12 ( 15 ) 2499 - 2505 2024.05
Research paper (journal)
BACKGROUND: Bone metastasis has various negative impacts. Activities of daily living (ADL) and quality of life (QOL) can be significantly decreased, survival may be impacted, and medical expenses may increase. It is estimated that at least 5% cancer patients might be suffering from bone metastases. In 2016, we published the Comprehensive Guidelines for the Diagnosis and Treatment of Bone Metastasis. Since then, the therapeutic outcomes for patients have gradually improved. As life expectancy is a major determinant of surgical intervention, the strategy should be modified if the prolongation of survival is to be achieved. AIM: To monitor how bone metastasis treatment has changed before and after launch of our guidelines for bone metastasis. METHODS: For advanced cancer patients with bone metastasis who visited the Department of Clinical Oncology at Akita University hospital between 2012 and 2023, parameters including the site and number of bone metastases, laboratory data, and survival time, were extracted from electronic medical records and the Katagiri score was calculated. The association with survival was determined for each factor. RESULTS: Data from 136 patients were obtained. The 1-year survival rate for the poor prognosis group with a higher Katagiri score was 20.0% in this study, which was 6% and an apparent improvement from 2014 when the scoring system was developed. Other factors significantly affecting survival included five or more bone metastases than less (P = 0.0080), and treatment with chemotherapy (P < 0.001), bone modifying agents (P = 0.0175) and immune checkpoint inhibitors (P = 0.0128). In recent years, advances in various treatment methods have extended the survival period for patients with advanced cancer. It is necessary not only to simply extend survival time, but also to maintain ADL and improve QOL. CONCLUSION: Various therapeutic interventions including surgical approach for bone metastasis, which is a disorder of locomotor organs, are increasingly required. Guidelines and scoring system for prognosis need to be revised promptly.
-
A case of hereditary breast and ovarian cancer syndrome of initially presented as cancer of unknown primary with lymph node metastases unveiled by genetic analysis.
Juri Yamada, Koji Fukuda, Tae Sugawara, Kenichi Makino, Kazuhiro Shimazu, Taichi Yoshida, Daiki Taguchi, Hanae Shinozaki, Yukihiro Terada, Hiroshi Nanjo, Hiroyuki Shibata
International cancer conference journal 13 ( 2 ) 139 - 143 2024.04
Research paper (journal)
Cancer of unknown primary (CUP) is a heterogeneous disease concept involving various malignant tumors. Understanding its pathophysiology is often difficult, together with its treatment. Here, we present a case of CUP with abdominal lymph node enlargement and elevated carbohydrate antigen 125 levels. It initially resembled a favorable prognosis type similar to ovarian cancer, but metastases were observed in cervical lymph nodes, indicating a somewhat atypical CUP compared to the typical ovarian cancer-like CUP. We identified a germline Breast Cancer 1 (BRCA1) p.L63* variant through a family history inquiry and BRCA analysis, indicating hereditary breast and ovarian cancer syndrome. The patient achieved near-complete remission with platinum-based therapy followed by poly (ADP-ribose) polymerase (PARP) inhibitor. The variant has shown sensitivity in both clinical and pathogenic reports in the ClinVar database of the National Institutes of Health. No clinical studies reported on the efficacy of PARP inhibitors specific to this variant, but our case demonstrated the sensitivity of platinum-based therapy followed by PARP inhibitor. Reports of CUP in hereditary breast and ovarian cancer syndrome are very rare, with only a single report in the literature.
-
Analysis of patients with colorectal cancer and brain metastases.
Matsuoka Y, Ota I, Seki H, Ito S, Kato S
Future Medicine, Colorect. Cancer 5 ( 3 ) 109 - 114 2016.08 [Refereed]
Research paper (journal) Domestic Co-author
-
Application of therapeutic drug monitoring of imatinib for individual treatment of gastrointestinal stromal tumor
Shimazu K, Yoshida T, Inoue M, Miura M, Shibata H
International Journal of Cancer Therapy and Oncology 4 ( 2 ) 2016.05 [Refereed]
Research paper (journal) Single author
-
Sudden and severe cardiotoxicity induced with pembrolizumab, its clinical course, therapeutic intervention, and outcome.
Tomohiro Matsumoto, Koji Fukuda, Taichi Yoshida, Kazuhiro Shimazu, Daiki Taguchi, Hanae Shinozaki, Katsuhito Seki, Takayuki Yamanaka, Mako Ootaka, Hiroshi Nanjyo, Hiroyuki Watanabe, Hiroyuki Shibata
International cancer conference journal 11 ( 1 ) 81 - 86 2022.01
Immune checkpoint inhibitors (ICIs), including cytotoxic T-lymphocyte associated antigen-4 inhibitors, and inhibitors of programmed cell death 1 and its ligand, are widely used in the treatment of several malignant tumors. Immune-related adverse events occur in two-thirds of recipients. Among them, cardiotoxicities are very rare (about 1%), albeit fatal. Pembrolizumab-induced cardiotoxicity in a patient was successfully treated with high-dose corticosteroids, and his cardiac function was maintained by adrenergic drugs and intra-aortic balloon pumping in the intensive care unit for 1 week. Cardiotoxicity with ICIs is an oncologic emergency, and should be managed in a pluridisciplinary setting involving cardiologists.
-
Guillain-Barré syndrome in a cancer patient treated with bevacizumab.
Daiki Taguchi, Sachiko Kamada, Taichi Yoshida, Koji Fukuda, Kazuhiro Shimazu, Masahiro Inoue, Masashiro Sugawara, Hiroshi Nanjyo, Katsunori Iijima, Hiroyuki Shibata
International cancer conference journal 7 ( 3 ) 87 - 92 2018.07
We describe a case of Guillain-Barré syndrome (GBS) in a patient treated with bevacizumab. Our case is a 60-year-old woman with Stewart-Treves syndrome (STS), and angiosarcoma of her left forearm, with onset 12 years after diagnosis with stage IIIA left breast cancer. She suffered from repeated distal metastases including skin, bone, and liver metastases. She underwent numerous treatments including left arm amputation, radiation, and chemotherapy, but her disease was resistant. Thereafter, she received bevacizumab. Two weeks following the first administration, she presented in poor physical condition. Although the cause was not specified at that time, bevacizumab was discontinued. At 1 month following first bevacizumab administration, she gradually developed dyspnea, and numbness in her tongue and hands. Soon after, she was emergently admitted to the hospital due to hyperventilation syndrome. On hospital day 4, she developed quadriparesis, and on hospital day 8, she was diagnosed with GBS following neurological testing. Treatment with intravenous immunoglobulins was started immediately upon diagnosis, and her neurological symptoms eventually resolved. A repeat challenge course of bevacizumab was avoided. Five months later, the patient perished from STS progression. GBS associated with malignancies and/or chemotherapies has been rarely described in patients with malignant lymphomas. Of note, there is only one reported case of GBS with bevacizumab. Furthermore, in some cases, GBS is lethal, and it should be considered in the differential diagnosis of patients treated with bevacizumab.
-
Effect of anti-PD-1 antibody, nivolumab on early gastric cancer.
Koji Fukuda, Taichi Yoshida, Kazuhiro Shimazu, Daiki Taguchi, Masahiro Inoue, Hiroshi Nanjyo, Hiroyuki Shibata
International cancer conference journal 6 ( 3 ) 98 - 103 2017.07
Immunomodulation treatment using anti-programmed cell death protein 1 antibody is a very promising treatment for various types of advanced cancers, including melanoma, non-small cell lung cancer, and renal cell carcinoma. However, the therapeutic effects on early cancers are still unknown. We experienced 2 cases of early gastric cancers coexisting advanced melanomas. In both cases, early gastric cancers did not respond to nivolumab. Both early gastric cancers did not express programed death ligand 1. It was speculated that immunotolerance was not fully established responsible for nivolumab in early gastric cancer, and for this reason, nivolumab could not shrink these tumors. We experienced 2 cases of early gastric cancer, where PD-L1 was negative, not responding to nivolumab.